Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Trial of Poor Performance Status Patients (ToPPS)
- Conditions
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 172
- Registration Number
- NCT00892710
- Locations
- 🇺🇸
Aventura Medical Center, Aventura, Florida, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Memorial Regional Cancer Center, Hollywood, Florida, United States
A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 70
- Registration Number
- NCT00887549
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)
- Conditions
- Interventions
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2011-02-24
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT00886678
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 38
- Registration Number
- NCT00868192
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2015-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT00867009
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reus, Spain
Study of Pemetrexed for Second-Line Pancreas Cancer
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 17
- Registration Number
- NCT00864513
- Locations
- 🇺🇸
Georgetown University Hospital/Lombardi Cancer Center, Washington, District of Columbia, United States
Trimodal Lung-Sparing Treatment of Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2009-03-11
- Last Posted Date
- 2020-08-25
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 9
- Registration Number
- NCT00859495
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 143
- Registration Number
- NCT00824408
- Locations
- 🇨🇦
1230.5.00106 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
🇧🇸1230.5.00118 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇨🇦1230.5.00114 Boehringer Ingelheim Investigational Site, Kelowna, British Columbia, Canada
Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment
- First Posted Date
- 2008-12-12
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT00807573
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
🇺🇸Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 718
- Registration Number
- NCT00806819
- Locations
- 🇺🇦
Boehringer Ingelheim Investigational Site, Vinnytsia, Ukraine
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.